Insider Selling: Option Care Health, Inc. (NASDAQ:OPCH) Insider Sells 30,996 Shares of Stock

Option Care Health, Inc. (NASDAQ:OPCH) insider Michael Bavaro sold 30,996 shares of the stock in a transaction on Friday, February 28th. The stock was sold at an average price of $33.26, for a total transaction of $1,030,926.96. Following the sale, the insider now owns 44,974 shares of the company’s stock, valued at approximately $1,495,835.24. This represents a 40.80 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Option Care Health Stock Up 0.5 %

OPCH opened at $34.12 on Wednesday. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.73 and a quick ratio of 1.32. Option Care Health, Inc. has a 12 month low of $21.39 and a 12 month high of $34.57. The stock has a market capitalization of $5.81 billion, a P/E ratio of 28.67, a P/E/G ratio of 2.30 and a beta of 1.35. The business has a 50 day simple moving average of $29.15 and a 200-day simple moving average of $28.09.

Institutional Investors Weigh In On Option Care Health

Hedge funds and other institutional investors have recently bought and sold shares of the business. Raymond James & Associates grew its stake in shares of Option Care Health by 6.3% during the 3rd quarter. Raymond James & Associates now owns 85,279 shares of the company’s stock worth $2,669,000 after purchasing an additional 5,049 shares during the period. International Assets Investment Management LLC boosted its holdings in Option Care Health by 3,029.7% during the third quarter. International Assets Investment Management LLC now owns 2,848 shares of the company’s stock worth $91,000 after buying an additional 2,757 shares in the last quarter. Wealth Enhancement Advisory Services LLC acquired a new position in Option Care Health during the third quarter worth about $206,000. State of Alaska Department of Revenue grew its position in Option Care Health by 3.8% during the third quarter. State of Alaska Department of Revenue now owns 19,871 shares of the company’s stock worth $621,000 after buying an additional 735 shares during the period. Finally, Nisa Investment Advisors LLC increased its holdings in Option Care Health by 7.0% in the third quarter. Nisa Investment Advisors LLC now owns 14,526 shares of the company’s stock valued at $455,000 after buying an additional 945 shares in the last quarter. Institutional investors and hedge funds own 98.05% of the company’s stock.

Wall Street Analysts Forecast Growth

OPCH has been the subject of a number of research reports. JMP Securities reaffirmed a “market outperform” rating and issued a $30.00 target price (down from $31.00) on shares of Option Care Health in a report on Friday, January 10th. UBS Group began coverage on Option Care Health in a research report on Thursday, December 5th. They set a “neutral” rating and a $26.00 price objective for the company. Barrington Research boosted their target price on Option Care Health from $33.00 to $38.00 and gave the company an “outperform” rating in a report on Thursday, February 27th. Jefferies Financial Group raised Option Care Health from a “hold” rating to a “buy” rating and increased their price target for the stock from $26.00 to $35.00 in a report on Thursday, January 23rd. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Option Care Health from $38.00 to $40.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, Option Care Health has an average rating of “Moderate Buy” and an average target price of $32.88.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.